USA flag logo/image

An Official Website of the United States Government

Unique Anti-microbial Rinse to Reduce Oral Inflammation

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
93984
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
HL101821
Solicitation Year:
N/A
Solicitation Topic Code:
NHLBI
Solicitation Number:
N/A
Small Business Information
BIOMEDICAL DEVELOPMENT CORPORATION
A152 ASTeCC Building Lexington, KY 40506-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2010
Title: Unique Anti-microbial Rinse to Reduce Oral Inflammation
Agency: HHS
Contract: 4R44HL101821-02
Award Amount: $710,270.00
 

Abstract:

DESCRIPTION (provided by applicant): Periodontal disease has been recently identified as a risk factor for increased morbidity and mortality for systemic diseases such as pancreatic cancer, cardiovascular disease (atherosclerosis, myocardial infarction, a nd stroke), and diabetes, as well as for pregnancy complications such as preterm birth. It is well established that periodontal disease results from microorganisms in dental plaque biofilm. Inflammatory reactions initiated by oral bacteria and their compon ents are implicated locally in the pathogenesis of periodontal tissue destruction, and may contribute to the development of systemic disease. While causality has yet to be confirmed, some studies have shown that oral health interventions may impact biologi cal markers of inflammation and disease. The goal of this project is to develop a prescription antimicrobial oral rinse to reduce bacterial bioburden in the oral cavity and combat oral disease and inflammation. Current oral rinse products are either fraugh t with side effects such as staining and taste alterations that limit their usage to acute settings, or are ineffective. Based on preliminary studies, the oral rinse developed herein is expected to be more effective than currently available prescription pr oducts without the side effects. The development of a highly effective oral rinse may have the potential to have a profound impact on public health and achieve significant commercial success. This study is a Fast-Track proposal that combines both Phase I a nd Phase II studies in one application. The Phase I portion has two Specific Aims: Aim 1. Compound Oral Rinse Formulations for Use in Clinical Trials Aim 2. Evaluate Dose-Response of the Oral Rinse in a Human Clinical Trial of Gingival Inflammation and Inv estigate Effects on Biological Markers Indicative of Systemic Disease. The Phase II portion has three Specific Aims: Aim 1. Compound Oral Rinse Formulations for Use in Clinical Trials Aim 2. Evaluate the Oral Rinse in a Human Clinical Trial of Gingivitis t o Satisfy FDA Requirements and Investigate Effects on Biological Markers Indicative of Systemic Disease. PUBLIC HEALTH RELEVANCE: Recent studies have linked oral bacteria to systemic diseases such as pancreatic cancer, diabetes, stroke and heart dis ease. Although it has yet to be proven that oral bacteria cause these diseases directly, there is some evidence that dental treatment may improve markers of disease. The development of a safe and effective mouthrinse that could remove harmful oral bacteria and potentially reduce the incidence of disease would have a significant impact on public health.

Principal Investigator:

Charles J. Gauntt
2103080636
GAUNTT@BIODEVCORP.COM

Business Contact:

Gregg Siegel
gsiegel@biodevcorp.com
Small Business Information at Submission:

BIOMEDICAL DEVELOPMENT CORPORATION
BIOMEDICAL DEVELOPMENT CORP 500 SANDAU, STE 200 SAN ANTONIO, TX 78216

EIN/Tax ID: 174233006
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No